Formoterol Turbuhaler + Budesonide/Formoterol Turbuhaler + Formoterol Turbuhaler
Phase 1Completed 0 watching 0 views this week๐ค Quiet
33
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
COPD Method Evaluation
Conditions
COPD Method Evaluation, Chronic Obstructive Pulmonary Disease Method Evaluation
Trial Timeline
Aug 1, 2011 โ Jun 1, 2012
NCT ID
NCT01257048About Formoterol Turbuhaler + Budesonide/Formoterol Turbuhaler + Formoterol Turbuhaler
Formoterol Turbuhaler + Budesonide/Formoterol Turbuhaler + Formoterol Turbuhaler is a phase 1 stage product being developed by AstraZeneca for COPD Method Evaluation. The current trial status is completed. This product is registered under clinical trial identifier NCT01257048. Target conditions include COPD Method Evaluation, Chronic Obstructive Pulmonary Disease Method Evaluation.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01257048 | Phase 1 | Completed |
Competing Products
20 competing products in COPD Method Evaluation